Original Publication Date: 1 June, 2016
Publication / Source: Immunotherapy
Authors: Murali Janakiram, Vipul Pareek, Haiying Cheng, Deepa M Narasimhulu & Xingxing Zang
Tumor immune evasion is one of the hallmarks of cancer, and expression of the B7 family of immune checkpoints (PD-L1, PD-L2, B7-H3, B7x and HHLA2) is one mechanism of immune evasion by tumors to suppress T-cell function. Antibodies blocking these interactions of B7–1/B7–2/CTLA-4 and PD-L1/PD-L2/PD-1 have had remarkable clinical success in several cancers and are less toxic than traditional chemotherapy.